Background: Lipid profile as a prognostic factor in terminal cancer patients is controversial. This study aimed to provide useful information related to the treatment of patients with terminal cancer by examining lipid profiles and their association with survival time.
Methods: We retrospectively reviewed the medical records of 428 inpatients who died while receiving palliative care a university hospital in Daegu during September 2015-September 2020 and then analyzed differences in survival times and the relative risk associated with lipid profiles.
Results: The mean survival of subjects with low low-density lipoprotein cholesterol (LDL-C) (<130 mg/dL) was 30.10 days, which was significantly shorter than that of subjects without (P<0.001). The mean survival of subjects with high triglyceride (TG) levels (≥150 mg/dL) was 32.95 days, which was shorter than subject without (P=0.006). The difference in survival time according to total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels was not statistically significant (P=0.068 and P=0.425, respectively). Multivariate Cox regression analysis showed that the hazard ratios of low LDL-C levels and high TG levels in relation to shorter survival times were 4.201 [95% confidence interval (CI), 2.578-6.259] and 1.492 (95% CI, 1.063-2.195), respectively.
Conclusions: Low LDL-C levels and high TG levels are correlated with survival time. However, a follow-up study on the lipid profile as a predictor of the survival time of patients with terminal cancer is necessary.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21037/apm-22-366 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Towards a Theory of Compassion Fatigue in Palliative Care and Oncology: A Systematic Scoping Review.
Am J Hosp Palliat Care
January 2025
Division of Supportive and Palliative Care, National Cancer Centre Singapore, Singapore.
Background: In their care of terminally ill patients, palliative care physicians and oncologists are increasingly predisposed to physical and emotional exhaustion, or compassion fatigue (CF). Challenges faced by physicians include complex care needs; changing practice demands, and sociocultural contextual factors. Efforts to better understand CF have, however, been limited.
View Article and Find Full Text PDFERK-USP9X-coupled regulation of thymidine kinase 1 promotes both its enzyme activity-dependent and its enzyme activity-independent functions for tumor growth.
Nat Struct Mol Biol
January 2025
Zhejiang Provincial Key Laboratory of Pancreatic Disease, Department of Gastroenterology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
Thymidine kinase 1 (TK1), a crucial enzyme in DNA synthesis, is highly expressed in various cancers. However, the mechanisms underlying its elevated expression and the implications for tumor metabolism remain unclear. Here we demonstrate that activation of growth factor receptors enhances TK1 expression.
View Article and Find Full Text PDFRIF1 integrates DNA repair and transcriptional requirements during the establishment of humoral immune responses.
Nat Commun
January 2025
Laboratory of Genome Diversification & Integrity, Max Delbrück Center for Molecular Medicine in the Helmholtz Association, 13125, Berlin, Germany.
The establishment of protective immune responses relies on the ability of terminally differentiated B cells to secrete a broad variety of antigen-specific antibodies with different effector functions. RIF1 is a multifunctional protein that promotes antibody isotype diversification via its DNA end protection activity during class switch recombination. In this study, we showed that RIF1 ablation resulted in increased plasmablast formation ex vivo and enhanced terminal differentiation into plasma cells upon immunization.
View Article and Find Full Text PDFCobalt-Catalyzed Hydroglycosylation of Alkynes for the Synthesis of Vinyl α-C-Glycosides.
Angew Chem Int Ed Engl
January 2025
Sichuan University, State Key Laboratory of Biotherapy, CHINA.
Herein we report a cobalt-catalyzed hydroglycosylation of terminal alkynes, employing bench-stable ortho-iodobiphenyl (oIB) substituted sulfides as glycosyl donors. This reaction occurs with high stereo- and regioselectivity to afford E-configured vinyl α-C-glycosides, a class of compounds nontrivial to access by previous methods. The use of a bis(oxazoline) ligand with bulky side chains is critical for the high selectivities observed.
View Article and Find Full Text PDFA Phase II Trial of Onapristone and Fulvestrant for Patients With ER+ and HER2- Metastatic Breast Cancer.
Clin Breast Cancer
December 2024
Medical Oncology and Palliative Care, Department of Medicine, Breast Cancer Disease Oriented Team, University of Wisconsin Carbone Cancer Center, University of Wisconsin School of Medicine and Public Health, Madison, WI 53792-3252.
Background: The SMILE study is a multi-institutional phase II clinical trial to determine the efficacy and safety of an antiprogestin, onapristone, in combination with fulvestrant as second-line therapy for patients with ER+, PgR+/-, HER2- metastatic breast cancer. This study was terminated early and herein, we report patient characteristics, and outcomes.
Methods: Eligibility criteria included disease progression on ≥2 lines of prior therapy, ECOG performance status ≤ 2, measurable disease per RECIST 1.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!